Abstract:This review addressed drug interactions precipitated by fruit juices other than grapefruit juice based on randomized controlled trials (RCTs). Literature was identified by searching PubMed, Cochrane Library, Scopus and Web of Science till December 30 2017. Among 46 finally included RCTs, six RCTs simply addressed pharmacodynamic interactions and 33 RCTs studied pharmacokinetic interactions, whereas seven RCTs investigated both pharmacokinetic and pharmacodynamic interactions. Twenty-two juice-drug combinations showed potential clinical relevance. The beneficial combinations included orange juice-ferrous fumarate, lemon juice-99mTc-tetrofosmin, pomegranate juice-intravenous iron during hemodialysis, cranberry juice-triple therapy medications for H. pylori, blueberry juice-etanercept, lime juice-antimalarials, and wheat grass juice-chemotherapy. The potential adverse interactions included decreased drug bioavailability (apple juice-fexofenadine, atenolol, aliskiren; orange juice-aliskiren, atenolol, celiprolol, montelukast, fluoroquinolones, alendronate; pomelo juice-sildenafil; grape juice-cyclosporine), increased bioavailability (Seville orange juice-felodipine, pomelo juice-cyclosporine, orange-aluminum containing antacids). Unlike furanocoumarin-rich grapefruit juice which could primarily precipitate drug interactions by strong inhibition of cytochrome P450 3A4 isoenzyme and P-glycoprotein and thus cause deadly outcomes due to co-ingestion with some medications, other fruit juices did not precipitate severely detrimental food-drug interaction despite of sporadic case reports. The extent of a juice-drug interaction may be associated with volume of drinking juice, fruit varieties, type of fruit, time between juice drinking and drug intake, genetic polymorphism in the enzymes or transporters and anthropometric variables. Pharmacists and health professionals should properly screen for and educate patients about potential adverse juice-drug interactions and help minimize their occurrence. Much attention should be paid to adolescents and the elderly who ingest medications with drinking fruit juices or consume fresh fruits during drug treatment. Meanwhile, more researches in this interesting issue should be conducted.

On the Assessment of Effects of Food on the Pharmacokinetics of Drugs in Early Development.

Food-drug Interactions Precipitated by Fruit Juices Other Than Grapefruit Juice: an Update Review

Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.

Evaluating Utilization of Tiny-TIM to Assess the Effect of Food on the Absorptions of Oral Drugs and its Application on Biopharmaceutical Modeling

Developing a Molecular Roadmap of Drug-Food Interactions

On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food

Analysis of the interplay of physiological response to food intake and drug properties in food-drug interactions

Selected Food/Herb-Drug Interactions: Mechanisms and Clinical Relevance

Drug-food Interactions in the Era of Molecular Big Data, Machine Intelligence, and Personalized Health

Drug interactions evaluation: An integrated part of risk assessment of therapeutics

Food‐Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012‐2022

Common Food and Drug Interactions.

[Drug/food interactions: an actual therapeutic outcome].

Food and Drug Interaction: Consequences for the Nutrition/Health Status

Key Factors for Improving Predictive Accuracy and Avoiding Overparameterization of the PBPK Absorption Model in Food Effect Studies of Weakly Basic Water-Insoluble Compounds in Immediate Release Formulations

Pharmacometabonomic Phenotyping Reveals Different Responses To Xenobiotic Intervention In Rats

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

Therapeutic Protein–Drug Interactions and Implications for Drug Development

New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process

Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development

Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs